Massa Horace, Nagar Anindyt M, Vergados Athanasios, Dadoukis Panagiotis, Patra Sudeshna, Panos Georgios D
1 Department of Ophthalmology, Geneva University Hospitals, Geneva, Switzerland.
*These authors contributed equally to this work.
J Int Med Res. 2019 Jan;47(1):31-43. doi: 10.1177/0300060518816884. Epub 2018 Dec 16.
Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti-vascular endothelial growth factor agents, and steroid implants with a focus on the new fluocinolone acetonide implant, ILUVIEN®. The results of the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) studies are also presented together with the results of real-world studies to support the clinical use of ILUVIEN® in achieving efficient resolution of DMO and improving vision and macular anatomy in this challenging group of patients.
糖尿病性黄斑水肿（DMO）是糖尿病视网膜病变的常见并发症，可能导致严重视力丧失。在本综述中，我们描述了DMO的病理生理学，并回顾了当前的治疗选择，如黄斑激光光凝、抗血管内皮生长因子药物和类固醇植入物，重点介绍新型氟轻松丙酮化物植入物ILUVIEN®。还介绍了氟轻松丙酮化物治疗糖尿病性黄斑水肿（FAME）研究的结果以及真实世界研究的结果，以支持ILUVIEN®在这一具有挑战性的患者群体中实现DMO有效消退、改善视力和黄斑解剖结构的临床应用。
